GlassScriptPhysician profile
Tabitha H Cousart
NPI 1982839197
$3,308.96
in general payments reported to CMS, 2019-2025
31 companies · $670 in 2025
The $670 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $364 · 2022: $1,195 · 2023: $722 · 2024: $359 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $606.51 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $467.87 | 2022-2025 | |
| Novo Nordisk INC | $329.73 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $180.91 | 2021-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $140.85 | 2021-2024 | Mounjaro, Emgality, Jardiance |
| Otsuka America Pharmaceutical, INC. | $134.39 | 2022-2024 | Rexulti |
| Pfizer INC. | $123.86 | 2021-2023 | |
| Amgen INC. | $116.43 | 2021-2023 | Otezla, Repatha |
| Dexcom, INC. | $113.29 | 2022-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $112.52 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.18 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.79 | 2022 | |
| Sanofi-Aventis U.S. LLC | $77.32 | 2022 | |
| Mylan Specialty L.P. | $72.55 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $66.01 | 2022-2023 | Xarelto |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $63.67 | 2021-2022 | |
| Becton, Dickinson and Company | $59.00 | 2023-2024 | Bd Safetyglide |
| Novartis Pharmaceuticals Corporation | $58.43 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.73 | 2023-2025 | Caplyta |
| Abbott Laboratories | $41.63 | 2022 | |
| Axsome Therapeutics, INC. | $40.74 | 2022-2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $40.14 | 2021-2022 | |
| Organogenesis INC. | $31.41 | 2021 | |
| Exact Sciences Corporation | $30.71 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $29.83 | 2022-2023 | Gardasil 9, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.37 | 2021-2023 | Xifaxan, Trulance |
| Organon LLC | $26.88 | 2023-2024 | Nexplanon |
| Idorsia Pharmaceuticals US INC | $23.93 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $23.81 | 2023 | Gemtesa |
| Astellas Pharma US INC | $23.72 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $21.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Cousart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.